US$ 21.85
cjc 1295 ipamorelin research peptide cjc-1295 igf-1 increase clinical data cjc-1295 ipamorelin igf-1 increase percentage studies CJC-1295 Ipamorelin 10mg
Description
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

DAVA Oncology's 5th Summit on Thoracic Malignancies

doi: 10.1016/0003-2697(69)90064-5

doi: 10.1016/S1470-2045(14)70381-X 58 SaitoHFukuharaTFuruyaNWatanabeKSugawaraSIwasawaSet al
